An out of specification (OOS) occurs when analytical results fall outside established specification ranges. There are guidelines from organizations like MHRA, CDER, and PIC/S for handling OOS events. OOS can occur during stability studies, finished products, or raw materials due to laboratory errors, process issues, or sample homogeneity problems. Investigations follow a phased approach starting with the quality control laboratory and then involving manufacturing operations if needed. The fate of an OOS batch may include reprocessing, reworking, or destruction depending on the investigation conclusions.
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Distribution, Electronic data handling and controlled documentation by Khushb...KhushbooKunkulol
This document discusses documentation, distribution, and electronic data handling procedures for pharmaceutical companies. It contains the following key points:
1. Documentation procedures ensure standardized and unambiguous procedures are followed to minimize errors. Distribution records must allow for efficient product recall if needed.
2. Electronic data handling uses computers to collect, store, and analyze data. It generates audit trails and records for activities like batch production. The ALCOA principles provide guidelines for ensuring electronic data is attributable, legible, contemporaneous, original, and accurate.
3. Controlled documents are subject to versioning and access restrictions to ensure only the correct version is used. Uncontrolled documents are not versioned and can be freely edited for reference purposes.
The document discusses current Good Manufacturing Practices (cGMP) according to the US Food and Drug Administration (FDA). It provides an overview of cGMP principles and requirements, including proper facilities and equipment design, documentation practices, and quality control. The document also summarizes key cGMP regulations and guidelines for manufacturing, processing, packaging, holding, testing, and distributing drug products. It outlines the important documents, facilities, equipment, production processes, and quality systems that must be in place to ensure consistent production of safe, effective pharmaceuticals.
Distribution records document the transfer of drug products from manufacturers to distributors and must include information such as product name and strength, manufacturer, lot number, quantity shipped, and recipient. They allow defective products to be recalled and ensure accountability. Records should contain sections for product information, transaction details, distribution information, and recipient information according to WHO guidelines. An example distribution record format was also presented.
This document discusses the qualification of dissolution test apparatus and validation of utility systems. It covers the installation qualification, operational qualification, and performance qualification of dissolution test apparatus. This includes procedures, acceptance criteria, and maintenance schedules for qualifying the apparatus. It also summarizes validation test functions and acceptance criteria for key utility systems like plant steam, pure steam, water for injection, and emergency power generators. The goal is to ensure dissolution testing provides reliable and reproducible results for assessing drug release and bioavailability.
Documentation in pharmaceutical industryPRANJAY PATIL
Pranjay Sadashiv Patil, a first year M.Pharm student, presented on documentation in pharmaceutical quality assurance. Documentation defines a system to minimize risks from misinterpretation or errors in oral communication. It includes specifications, test procedures, distribution records, and electronic data handling. Specifications provide parameters and limits for materials, equipment, and products. Test procedures must validate compliance to the end of shelf life. Controlled documents require approval and management of changes, while uncontrolled copies are for reference with a watermark.
An out of specification (OOS) occurs when analytical results fall outside established specification ranges. There are guidelines from organizations like MHRA, CDER, and PIC/S for handling OOS events. OOS can occur during stability studies, finished products, or raw materials due to laboratory errors, process issues, or sample homogeneity problems. Investigations follow a phased approach starting with the quality control laboratory and then involving manufacturing operations if needed. The fate of an OOS batch may include reprocessing, reworking, or destruction depending on the investigation conclusions.
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Distribution, Electronic data handling and controlled documentation by Khushb...KhushbooKunkulol
This document discusses documentation, distribution, and electronic data handling procedures for pharmaceutical companies. It contains the following key points:
1. Documentation procedures ensure standardized and unambiguous procedures are followed to minimize errors. Distribution records must allow for efficient product recall if needed.
2. Electronic data handling uses computers to collect, store, and analyze data. It generates audit trails and records for activities like batch production. The ALCOA principles provide guidelines for ensuring electronic data is attributable, legible, contemporaneous, original, and accurate.
3. Controlled documents are subject to versioning and access restrictions to ensure only the correct version is used. Uncontrolled documents are not versioned and can be freely edited for reference purposes.
The document discusses current Good Manufacturing Practices (cGMP) according to the US Food and Drug Administration (FDA). It provides an overview of cGMP principles and requirements, including proper facilities and equipment design, documentation practices, and quality control. The document also summarizes key cGMP regulations and guidelines for manufacturing, processing, packaging, holding, testing, and distributing drug products. It outlines the important documents, facilities, equipment, production processes, and quality systems that must be in place to ensure consistent production of safe, effective pharmaceuticals.
Distribution records document the transfer of drug products from manufacturers to distributors and must include information such as product name and strength, manufacturer, lot number, quantity shipped, and recipient. They allow defective products to be recalled and ensure accountability. Records should contain sections for product information, transaction details, distribution information, and recipient information according to WHO guidelines. An example distribution record format was also presented.
This document discusses the qualification of dissolution test apparatus and validation of utility systems. It covers the installation qualification, operational qualification, and performance qualification of dissolution test apparatus. This includes procedures, acceptance criteria, and maintenance schedules for qualifying the apparatus. It also summarizes validation test functions and acceptance criteria for key utility systems like plant steam, pure steam, water for injection, and emergency power generators. The goal is to ensure dissolution testing provides reliable and reproducible results for assessing drug release and bioavailability.
Documentation in pharmaceutical industryPRANJAY PATIL
Pranjay Sadashiv Patil, a first year M.Pharm student, presented on documentation in pharmaceutical quality assurance. Documentation defines a system to minimize risks from misinterpretation or errors in oral communication. It includes specifications, test procedures, distribution records, and electronic data handling. Specifications provide parameters and limits for materials, equipment, and products. Test procedures must validate compliance to the end of shelf life. Controlled documents require approval and management of changes, while uncontrolled copies are for reference with a watermark.
cGMP Guidelines According to Schedule MANKUSH JADHAV
This document provides an overview of cGMP guidelines according to Schedule M. It defines cGMP and outlines key areas that must be addressed including personnel, premises, equipment, standard operating procedures, raw materials, self inspections, master formula records, batch manufacturing records, warehousing, and validation. The guidelines ensure quality products are consistently produced and that quality is built into every step of the manufacturing process.
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
The document discusses the pharmaceutical industry development process in India. It outlines the legal requirements and licenses needed to manufacture or import APIs and drugs. Companies must seek approval from the DCGI and adhere to CDSCO guidelines. The application process requires submitting chemical, pharmaceutical, pre-clinical and clinical data. Various forms are used for obtaining manufacturing, import, and sales licenses from the CDSCO. The CDSCO-SUGAM project aims to streamline approval processes.
This document discusses guidelines for handling Out of Specification (OOS) test results in the pharmaceutical industry. It provides an overview of the history of OOS guidelines, including FDA audits in the 1980s-90s that identified issues like "testing until pass", which led the FDA to publish formal OOS guidelines in 2006. The document outlines the OOS investigation process, which should first thoroughly check for laboratory errors and assign a cause, then may proceed to extended investigations including retesting or plant investigations if no error is found. Tools like 5M analysis and the five whys technique can be used to identify and analyze the root cause.
The document provides an overview of pre-formulation, which involves determining the physicochemical properties of a drug substance prior to developing a dosage form. It discusses the goals of pre-formulation to formulate an efficacious dosage form with good bioavailability. The protocol involves characterizing the physical, chemical, solubility, stability and compatibility properties of the drug. Key aspects covered include polymorphism, hygroscopicity, particle size, solubility, dissolution, stability in solution and solid state, and compatibility with excipients. The information guides subsequent formulation development.
PIC/S is an organization that was established to harmonize and improve Good Manufacturing Practice standards among member countries. It brings together regulatory authorities and pharmaceutical quality systems to ensure uniformity. PIC/S provides guidelines for industry, inspectors, and regulatory authorities to facilitate information sharing and mutual understanding, with the goal of protecting public health by helping to ensure the quality and safety of medical products globally.
The document discusses process validation for pharmaceutical manufacturing. It defines process validation and describes the objectives of validating manufacturing processes to consistently produce drugs that meet quality standards. The document outlines the types of process validation, including prospective, concurrent, retrospective, and revalidation. It also discusses selecting and evaluating industrial processes for tablet production, in-process testing, annual product reviews, and references.
This document discusses various types of documentation required in the pharmaceutical industry, including master formula records (MFR), drug master files (DMF), and generic drug development. It defines MFRs as approved master documents that describe the full manufacturing process for a specific batch size. It provides details on the content required for MFRs based on guidelines from WHO, Health Canada, and the US CFR. It also discusses the purpose and types of DMFs submitted to the FDA, including Type 1 for manufacturing facilities, Type 2 for drug substances/products, and others. Finally, it briefly mentions the Hatch-Waxman Act as it relates to generic drug development.
Pharmaceutical packaging serves several important functions:
1) It protects drugs from external environmental factors like light, moisture, and contamination.
2) Packaging identifies drug products, provides instructions for proper use, and ensures safety and efficacy.
3) Packaging types include bottles, blister packs, vials, and other containers/closures that are evaluated through testing to ensure sterility, integrity, and that they do not interact with drug contents.
The document is a presentation on post-approval changes to bulk active chemicals. It discusses FDA guidance called BACPAC (Bulk Active Chemicals & Post Approval Changes) which provides recommendations for post-approval changes to drug substance synthesis, including site, scale and equipment changes as well as specification and manufacturing process changes. The guidance covers assessing equivalence after changes and determining the appropriate reporting category based on the potential effects of changes.
Qualification and Validation have big Weightage in the Regulatory Compliance and GMP. Qualification and Validation only can guarantee about the Product Safety, Integrity, Strength, Purity and Quality assurance.
This document summarizes the ICH guideline for stability testing. The ICH provides guidance on stability testing to ensure drug quality over time under various environmental conditions. Key aspects covered include the objectives of stability testing, variables that affect stability, terminology, and ICH guidelines Q1A through Q1F which provide detailed recommendations on stability testing procedures, data evaluation, and submissions for registration.
Documentation is an integral part of good manufacturing practices. It defines a system of information and control so that risks so inherent in misinterpretation and/or error in oral communication are minimized.
Various techniques for study of Crystal PropertiesCooling Crystal
The document discusses various techniques used to characterize crystals and study their properties, including optical microscopy, etching, X-ray diffraction, FT-IR spectroscopy, thermal analysis, UV-visible spectroscopy, emission spectrometry, microhardness measurements, and vibrating sample magnetometry. It also summarizes a research paper on the formulation and evaluation of co-crystals of the poorly water soluble drug darunavir with succinic acid using different analytical techniques. The prepared co-crystals showed improved solubility, dissolution rate, flowability and stability compared to the pure drug.
This document provides an overview of current good manufacturing practice (cGMP) guidelines for active pharmaceutical ingredients (APIs) according to the US Food and Drug Administration (FDA). It discusses cGMP requirements for personnel responsibilities and training, facility design and maintenance, process utilities, containment practices, documentation and record keeping, and control of contamination during API manufacturing. The document is intended to provide guidance on complying with cGMP standards to ensure the quality of APIs.
The document provides an overview of current good manufacturing practices (cGMP) as defined by the World Health Organization (WHO). It discusses key aspects of cGMP including personnel, facilities, equipment, material management, quality management, manufacturing operations, validation, sterile products, security, documentation, and records. The goal of cGMP is to consistently produce pharmaceutical products that meet quality standards for their intended use and legal requirements.
The document discusses specifications and submission of documents for pharmaceutical products. It provides definitions and types of specifications for active materials, packing materials, intermediates, bulk, and finished products. It also discusses test procedures, protocols, reports, distribution records, electronic data handling, concepts of controlled vs uncontrolled documents, and submissions to regulators like DMFs, CTD, and eCTD. Specifications include parameters and acceptance limits. Test procedures must be validated and may reference official substances. Protocols, reports, and distribution records are important documentation for manufacturing and quality control. Electronic data handling can streamline documentation but has challenges around costs, connectivity, security, and validation.
The document provides information on the development and importance of pharmaceutical documentation. It discusses different types of documents including commitment documents like New Drug Applications and Drug Master Files, directive documents like specifications and standard operating procedures, and record documents like batch production records and protocols. The document also outlines general requirements and guidelines for designing documentation systems in accordance with cGMP.
cGMP Guidelines According to Schedule MANKUSH JADHAV
This document provides an overview of cGMP guidelines according to Schedule M. It defines cGMP and outlines key areas that must be addressed including personnel, premises, equipment, standard operating procedures, raw materials, self inspections, master formula records, batch manufacturing records, warehousing, and validation. The guidelines ensure quality products are consistently produced and that quality is built into every step of the manufacturing process.
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
The document discusses the pharmaceutical industry development process in India. It outlines the legal requirements and licenses needed to manufacture or import APIs and drugs. Companies must seek approval from the DCGI and adhere to CDSCO guidelines. The application process requires submitting chemical, pharmaceutical, pre-clinical and clinical data. Various forms are used for obtaining manufacturing, import, and sales licenses from the CDSCO. The CDSCO-SUGAM project aims to streamline approval processes.
This document discusses guidelines for handling Out of Specification (OOS) test results in the pharmaceutical industry. It provides an overview of the history of OOS guidelines, including FDA audits in the 1980s-90s that identified issues like "testing until pass", which led the FDA to publish formal OOS guidelines in 2006. The document outlines the OOS investigation process, which should first thoroughly check for laboratory errors and assign a cause, then may proceed to extended investigations including retesting or plant investigations if no error is found. Tools like 5M analysis and the five whys technique can be used to identify and analyze the root cause.
The document provides an overview of pre-formulation, which involves determining the physicochemical properties of a drug substance prior to developing a dosage form. It discusses the goals of pre-formulation to formulate an efficacious dosage form with good bioavailability. The protocol involves characterizing the physical, chemical, solubility, stability and compatibility properties of the drug. Key aspects covered include polymorphism, hygroscopicity, particle size, solubility, dissolution, stability in solution and solid state, and compatibility with excipients. The information guides subsequent formulation development.
PIC/S is an organization that was established to harmonize and improve Good Manufacturing Practice standards among member countries. It brings together regulatory authorities and pharmaceutical quality systems to ensure uniformity. PIC/S provides guidelines for industry, inspectors, and regulatory authorities to facilitate information sharing and mutual understanding, with the goal of protecting public health by helping to ensure the quality and safety of medical products globally.
The document discusses process validation for pharmaceutical manufacturing. It defines process validation and describes the objectives of validating manufacturing processes to consistently produce drugs that meet quality standards. The document outlines the types of process validation, including prospective, concurrent, retrospective, and revalidation. It also discusses selecting and evaluating industrial processes for tablet production, in-process testing, annual product reviews, and references.
This document discusses various types of documentation required in the pharmaceutical industry, including master formula records (MFR), drug master files (DMF), and generic drug development. It defines MFRs as approved master documents that describe the full manufacturing process for a specific batch size. It provides details on the content required for MFRs based on guidelines from WHO, Health Canada, and the US CFR. It also discusses the purpose and types of DMFs submitted to the FDA, including Type 1 for manufacturing facilities, Type 2 for drug substances/products, and others. Finally, it briefly mentions the Hatch-Waxman Act as it relates to generic drug development.
Pharmaceutical packaging serves several important functions:
1) It protects drugs from external environmental factors like light, moisture, and contamination.
2) Packaging identifies drug products, provides instructions for proper use, and ensures safety and efficacy.
3) Packaging types include bottles, blister packs, vials, and other containers/closures that are evaluated through testing to ensure sterility, integrity, and that they do not interact with drug contents.
The document is a presentation on post-approval changes to bulk active chemicals. It discusses FDA guidance called BACPAC (Bulk Active Chemicals & Post Approval Changes) which provides recommendations for post-approval changes to drug substance synthesis, including site, scale and equipment changes as well as specification and manufacturing process changes. The guidance covers assessing equivalence after changes and determining the appropriate reporting category based on the potential effects of changes.
Qualification and Validation have big Weightage in the Regulatory Compliance and GMP. Qualification and Validation only can guarantee about the Product Safety, Integrity, Strength, Purity and Quality assurance.
This document summarizes the ICH guideline for stability testing. The ICH provides guidance on stability testing to ensure drug quality over time under various environmental conditions. Key aspects covered include the objectives of stability testing, variables that affect stability, terminology, and ICH guidelines Q1A through Q1F which provide detailed recommendations on stability testing procedures, data evaluation, and submissions for registration.
Documentation is an integral part of good manufacturing practices. It defines a system of information and control so that risks so inherent in misinterpretation and/or error in oral communication are minimized.
Various techniques for study of Crystal PropertiesCooling Crystal
The document discusses various techniques used to characterize crystals and study their properties, including optical microscopy, etching, X-ray diffraction, FT-IR spectroscopy, thermal analysis, UV-visible spectroscopy, emission spectrometry, microhardness measurements, and vibrating sample magnetometry. It also summarizes a research paper on the formulation and evaluation of co-crystals of the poorly water soluble drug darunavir with succinic acid using different analytical techniques. The prepared co-crystals showed improved solubility, dissolution rate, flowability and stability compared to the pure drug.
This document provides an overview of current good manufacturing practice (cGMP) guidelines for active pharmaceutical ingredients (APIs) according to the US Food and Drug Administration (FDA). It discusses cGMP requirements for personnel responsibilities and training, facility design and maintenance, process utilities, containment practices, documentation and record keeping, and control of contamination during API manufacturing. The document is intended to provide guidance on complying with cGMP standards to ensure the quality of APIs.
The document provides an overview of current good manufacturing practices (cGMP) as defined by the World Health Organization (WHO). It discusses key aspects of cGMP including personnel, facilities, equipment, material management, quality management, manufacturing operations, validation, sterile products, security, documentation, and records. The goal of cGMP is to consistently produce pharmaceutical products that meet quality standards for their intended use and legal requirements.
The document discusses specifications and submission of documents for pharmaceutical products. It provides definitions and types of specifications for active materials, packing materials, intermediates, bulk, and finished products. It also discusses test procedures, protocols, reports, distribution records, electronic data handling, concepts of controlled vs uncontrolled documents, and submissions to regulators like DMFs, CTD, and eCTD. Specifications include parameters and acceptance limits. Test procedures must be validated and may reference official substances. Protocols, reports, and distribution records are important documentation for manufacturing and quality control. Electronic data handling can streamline documentation but has challenges around costs, connectivity, security, and validation.
The document provides information on the development and importance of pharmaceutical documentation. It discusses different types of documents including commitment documents like New Drug Applications and Drug Master Files, directive documents like specifications and standard operating procedures, and record documents like batch production records and protocols. The document also outlines general requirements and guidelines for designing documentation systems in accordance with cGMP.
The document provides information on documentation in the pharmaceutical industry including:
1. It emphasizes the importance of documentation for industries and describes protocols regarding documentation and their management.
2. Documentation is the key to GMP compliance and ensures traceability of all development, manufacturing, and testing activities. It provides a route for auditors to assess quality operations.
3. The most common types of documents used for GMP are described, including quality manuals, standard operating procedures, batch records, test methods, and specifications.
Documentation with respect to release of finished pharmaceutical productMadhuraNewrekar
Documentation is a crucial part of the quality assurance system and is needed in every aspect of pharmaceutical manufacturing. Important documentation with respect to final product release in pharmaceutical industry is explained in brief.
This document discusses the validation of raw materials used in pharmaceutical manufacturing. It defines validation as demonstrating through documented evidence that a process will consistently produce a product meeting predetermined specifications. The document outlines a 7 step process for validating raw materials: 1) List all raw materials needed, 2) Identify at least two suppliers for each material, 3) Qualify new suppliers by inspecting facilities, 4) Obtain supplier certificates of analysis and samples, 5) Establish specifications for each material, 6) Establish test procedures, 7) Establish sampling procedures. The validation process confirms raw materials meet specifications and ensures uniform, high quality batches.
It's an assignment on selected topics on Pharmaceuticals. Which are
1. Quality Management system in Pharmaceutical Industry
2. Quality Assurance and Quality Control in Pharmaceutical Industry
3. Difference between Quality Assurance and Quality Control
4. Briefly describe Pharmacopoeia, Drug Formulary, Drug compendia,
Pharmaceutical codex
5. Short notes on British Pharmacopoeia, US Pharmacopoeia,
European Pharmacopoeia, Japanese Pharmacopoeia, British
Pharmaceutical Codex
6. What is monograph in Pharmacopoeia? What does it contain?
documentation in pharmaceutical industry.pdfSoumiliPaul1
Documentation in the pharmaceutical industry plays a crucial role in maintaining quality, compliance, and safety standards. It encompasses standard operating procedures, quality audits, review of quality documentation, and generation of various reports and distribution records. Master formula records provide complete descriptions of all aspects of manufacturing, packing, and quality control. Quality audits verify that quality activities comply with plans and that arrangements are suitable to achieve objectives. Documentation includes internal audits by a company's employees and external audits by separate organizations.
1. Pharmaceutical analysis involves identifying and quantifying drugs in raw materials, dosage forms, and biological fluids using physical, chemical, biological, and other methods.
2. It is important for ensuring safety, efficacy, stability, and quality of pharmaceutical products. Analytical methods are used to determine identity, purity, content, impurities, and shelf life.
3. Sources of error in pharmaceutical analysis include inaccurate sample preparation, instrument malfunctions, and systematic or random errors in analytical procedures. Validating methods helps ensure accuracy and precision.
The document provides guidelines for specifications of new drug substances and products. It discusses setting specifications based on development data and stability studies. Universal tests for drug substances include identification, assay, impurities. For products, additional tests depend on dosage form and may include dissolution, uniformity, sterility. The guidelines provide concepts for justifying specifications and periodic testing. They apply principles for biotech products, addressing characterization, analytical validation, process controls, and linking specifications to manufacturing and clinical data.
This document provides summaries of ICH Q series guidelines related to pharmaceutical quality. The Q series addresses topics such as stability testing, analytical validation, impurities, pharmacopoeias, quality of biotechnological products, specifications for drug substances and products, good manufacturing practices, pharmaceutical development, quality risk management, and pharmaceutical quality systems. The guidelines provide recommendations for testing protocols, validation procedures, acceptance criteria, and ensuring quality across the lifecycle of drug manufacturing and development.
Current Good Manufacturing Practices (cGMP) are followed by pharmaceutical and biotechnology companies
Items are manufactured to specific requirements including identity, strength, quality, and purity. Good Manufacturing Practices are regulated by the Food and Drug Administration (FDA)
The document discusses the International Conference on Harmonization (ICH), which aims to harmonize technical requirements for pharmaceutical registration across regions to ensure safety and efficacy. ICH involves regulators and industry from the EU, Japan, and US. The objectives of ICH include increasing international harmonization, developing pharmaceuticals efficiently, promoting public health, and minimizing animal testing. ICH guidelines cover quality, efficacy, safety, and multidisciplinary topics.
This document provides an overview of pharmaceutical product development. It discusses the objectives of product development which include designing quality products and manufacturing processes to consistently deliver intended performance. It also covers regulations related to preformulation, formulation development, stability assessment, and quality control testing of different dosage forms. The document outlines guidelines from organizations like ICH and WHO for various stages of product development.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved, to respond to the increasingly global face of drug development. ICH’s mission is to achieve greater harmonisation worldwide to ensure that safe, effective, and high quality medicines are developed and registered in the most resource-efficient manner. On 23 October 2015, ICH announced organisational changes as it marks 25 years of successful harmonisation.
Good Laboratory Practice (GLP) guidelines provide standards for laboratory experiments and tests performed to support research, nonclinical studies, and regulatory submissions. The key goals of GLP are to ensure quality, reliability, and integrity of data through adherence to standard operating procedures, trained personnel, appropriate facilities and equipment, records management, and quality control. GLP aims to promote valid and robust research that can be reproduced internationally and supports regulatory review and decision making.
ICH Guideline Q8 Pharmaceutical DevelopmentBINDIYA PATEL
The document discusses ICH Q8 guidelines, which aim to provide harmonized guidance for pharmaceutical development. It introduces key concepts like design space and risk-based approaches. The guidelines encourage developing products and processes based on scientific understanding of critical quality attributes and how they are impacted by material attributes and process parameters. This facilitates continuous improvement and assurance of quality without need for regulatory review when operating within the approved design space. Overall, ICH Q8 promotes moving from quality by testing to quality by design.
This document provides guidance for registration applications on reporting and controlling degradation products in new drug products. Any degradation product observed above the identification threshold in stability studies should be identified. Analytical procedures must be validated to detect and quantify degradation products. Results should be reported for batches used in testing and batches representative of the commercial process. Degradation products present below identification thresholds usually do not need identification, unless they are unusually potent or toxic.
This document discusses documentation practices in the pharmaceutical industry. It begins by defining documentation and explaining its importance. Documentation provides written records of processes, ensures regulatory compliance, and allows for traceability and investigation. The document then discusses types of documents used like specifications, standard operating procedures, batch records, and quality control records. It explains the purpose and requirements for key documents like master formula records, batch production records, and material records. Overall, the document emphasizes that documentation is essential for quality assurance and compliance in the pharmaceutical industry.
1. GMP aims to ensure quality, safety and efficacy of pharmaceutical products through proper manufacturing and quality control.
2. Key aspects of GMP include facilities and equipment design, sanitation, personnel training, validation processes, documentation systems, and quality control testing.
3. Adhering to GMP guidelines helps manufacturers consistently produce pharmaceuticals that meet specifications and protects patients from defective products.
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
Assessment and Planning in Educational technology.pptxKavitha Krishnan
In an education system, it is understood that assessment is only for the students, but on the other hand, the Assessment of teachers is also an important aspect of the education system that ensures teachers are providing high-quality instruction to students. The assessment process can be used to provide feedback and support for professional development, to inform decisions about teacher retention or promotion, or to evaluate teacher effectiveness for accountability purposes.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
3. What is Documentation ?
Document is a written report or record that
provides information
Documentation is a method of preparing a
written material, which describes the process
in terms of specifications ,instructions etc.
Document is a piece of written, printed or
electronic matter that provides information or
evidence.
A Good Documentation is essential part of QA
system .
3
4. Importance of Documentation
It provides the working details necessary for
manufacturing, packaging, quality control.
Reduce the risk of mistakes inherent in verbal
communication.
They help in decreasing the batch to batch
variation so that quality of product is kept with in
the limit of acceptability.
Documentation and records are essentials for
obtaining ACCREDIATION ,certification of ISO, and
approval by Federal bodies.
4
5. Why Documentation?
There is a saying in the pharmaceutical
industry:
'if it hasn't been documented, then it
hasn't happened!'
“YOUR DOCUMENTATION IS AN
ADVERTISEMENT FOR YOUR WORK .
5
6. Specification
It is define as a set of parameters expected
to be met by a particular materials, peace of
equipments or any such object.
Every specification is a company's unique
document and it must have certain common
contents and thereafter each type of
document should have some specific
contents.
6
7. In case of pharmaceutical products we need
specifications for
Active and inactive starting materials
Primary ,printed and other packaging materials
Intermediate and bulk products
Finished pharmaceutical products
7
8. A document specification contains several parts:
a description of the audience(s) for the
document.
a detailed outline giving the structure and
contents of the document.
a work plan showing who is responsible for each
part of the document.
what the deadlines are for completing each
task.
8
9. Three purposes for document specifications:
In the workplace, formal document specifications
serve three important functions:
economy of effort,
work planning,
writing organization.
9
10. Common Contents
1.Name of the company and its address or location.
2.Title of the document viz. “specification”
3.Date of issue and implementation, effective date,
date of preparation, checking and authorisation,
proposed date of review.
4.Names and signature of persons preparing,
checking, and authorising the specification.
5.Unique identification number
6.Pharmacopoieal or other references
7.Circulation list
10
11. Specific Contents
1. Specification for active and inactive
starting materials.
2. Specification for packaging materials.
3. Specification for intermediate and bulk
products.
4. Specification for finished products.
11
12. Active and inactive starting materials
1.Name of material.
2.Code number references.
3.Pharmacopoial reference to the specific monograph.
4.Qualitative and quantitative requirements,
Physical and chemical characterisation,
microbiological standards and assay etc. Acceptance
limits, covering tests and limits for identity, purity.
5.Name of approved suppliers and original
manufacturer.
12
13. 6.Direction for sampling and testing or reference
to the procedures.
7.Storage conditions and safety precautions.
8.The maximum period of storage before re-
examination.
9.Details of or ref. to test method to be used to
assess compliance with the specification.
13
14. Packaging material
1.Name of material.
2.Code number reference.
3.Description of nature, dimensions, and materials
of construction of the components with quality
standards, control limits, mould reference,
drawing and details of the test.
4.List of approved supplies/manufacturers.
5.Sampling instructions.
6.storage conditions.
14
15. 7.Frequency of re-examination of stored
components.
8.Details of reference to the test methods to be
used to asses compliance with the specification.
9.A file of reference specimens of current printed
packaging materials should be maintained.
this should include a colour comparison
standard also.
each specimens in this must be certified by
the QC personnel.
15
16. Intermediate and bulk product
The following things should be added to the
common contents.
It should be available if these are purchased or
dispatched
or if data obtained from intermediate products
are used in the evaluation of the finished
products.
These specifications should be similar to starting
material or finished products .
16
17. Finished Products
1.Name of the product
2.Code number reference
3.Names of the ingredients
4.The formula or reference to the formula
5.A description of dosage forms and package
details.
6.Direction for sampling and testing or reference
to procedures.
17
18. 7.The qualitative and quantitative requirements
with acceptance limits.
8.The storage conditions and precautions, if
applicable.
9.Shelf life.
18
24. New Drug Substance
The following tests and acceptance criteria are
considered generally applicable to new drug
substances.
Description : a qualitative statement about
the state (e.g. Solid, liquid) and color of the new
drug substance. If any of these characteristics
change during storage ,this change should be
investigated and appropriate action taken.
24
25. Identification : identification testing should
optimally be able to discriminate between
compounds of closely related structure which
are likely to be present.
Identification tests should be specific for the
new drug substance, e.g., infrared
spectroscopy.
25
26. Assay : A specific, stability indicating procedure
should be included to determine the content of new
drug substance. In many cases it is possible to
employ the same procedure (e. g., HPLC) for both
assay of the new drug substance and quantitation
of impurities.
26
27. Impurities : Organic and inorganic impurities
and residual solvents are included in this category.
(Refer to the ICH Guidelines Impurities in new
drug substances and Residual solvents in
pharmaceuticals for detailed information.)
as per the ICH guideline Q3 A
27
29. Organic impurities
This may arise during the manufacturing process
or during the storage, they may be identified or
unidentified and volatile or non-volatile, it
includes,
starting material
by-product
intermediates
degradation product
ligands, catalyst and reagents
29
30. Inorganic impurities
They may arise in manufacturing process,
they may be known and identified. It
includes,
Reagent, ligands and catalyst
Heavy metals
Inorganic solvents
Other materials ( e.g. charcoal )
30
31. Residual solvents
This are the organic and inorganic solvents
which is used during the manufacturing, it
may be easily not removed by
manufacturing process.
This are generally of known toxicity.
31
32. Limits
Each identified specified impurity.
Each identified unspecified impurity at
or above 0.1%.
Any unspecified impurity, with a limit of
not more than 0.1%.
Total impurities.
32
33. New Drug Product
Description : A qualitative description of the
dosage form should be provided ( e.g., size,
shape and color).
Identification
Assay
Impurities
33
34. Specific tests/ Criteria
when the tests have an impact on the quality of
drug substance and drug product.
Tests other than this may be needed in
particular situations or as new information
become available.
34
35. Test
1.
Physicochemic-
al properties
pH of aqueous solution, melting point
and refractive index.
2. Particle size For some new drug substance intended
for use in solid or suspension drug
product, particle size have a significant
effect on dissolution rates,
bioavailability, and/ or stability.
3.Polymeric
form
Some new drug substances exist in
different crystalline form which differ in
their physical properties.
4.Water
content
This test is important in cases where the
new drug substance is known to be
hygroscopic or degraded by moisture
35
38. Protocol
Protocols are written records clearly defining the
objectives and methods that will be used for the
validation programs.
An important part of the protocol is the
description of the testing method including who
will test the system, how they will test it and
what data is to be collected and reported.
38
39. Computerized system protocols often include
the three distinct stages as described in PMA
reports:
Installation Qualification (IQ)
Operational Qualification (OQ)
Performance Qualification (PQ).
39
43. Protocol Changes
Document requirements specifies that who and
how changes can be done to parameters,
thresholds, and acceptance criteria.
It is not impossible to make changes after or
during testing, but these changes must be
properly implemented and approved to be
validated.
43
44. Protocol for Documentations
1.Serial number of the Batch Manufacturing
Record.
2.Name of the product.
3.Reference to Master Formula Record.
4.Batch/Lot number.
5.Batch/Lot size.
6.Date of commencement of manufacture and
date of completion of manufacture.
44
45. 7.Date of manufacture and assigned date of
expiry.
8.Date of each step in manufacturing.
9.Names of all ingredients with the grade given
by the quality control department.
10.Quality of all ingredients.
11. Control reference numbers for all ingredients.
12. Time and duration of blending, mixing, etc.
whenever applicable.
13. pH of solution whenever applicable.
45
46. 14. Filter integrity testing records.
15. Temperature and humidity records whenever
applicable.
16. Records of plate-counts whenever applicable.
17. Results of pyrogen and/or bacterial endotoxin
& toxicity.
18. Results of weight or volume of drug filled in
containers.
19. Bulk sterility in case of aseptically filled
products.
20. Leak test records.
46
47. 21. Inspection records.
22. Sterilization records including autoclave
leakage test records, load details, date, duration,
temperature, pressure, etc.
23. Container washing records.
24. Total number of containers filled.
25.Total numbers of containers rejected at each
stage.
26. Theoretical yield, permissible yield, actual yield
and variation thereof.
27. Clarification for variation in yield beyond
permissible yield.
47
48. 28. Reference numbers of relevant analytical
reports.
29. Details of reprocessing, if any.
30. Name of all operators carrying out different
activities.
31.Environmental monitoring records.
32. Specimens of printed packaging materials.
33. Records of destruction of rejected containers
printed packaging and testing.
34. Signature of competent technical staff
responsible for manufacture and testing.
48
50. Report
Documentation and records used throughout the
manufacturing process, as well as supporting
processes ( e. g. Quality Control or Quality
Assurance)
It includes,
Batch Record Forms
Bill of materials ( BOM)
Specifications
50
51. Policies
Protocols
Standard Operation Procedure (SOPs)
Work Instructions (WIs)
Check lists
Forms/ long sheets
Certificates of Analyses or Certificates of
Compliance
Technical transfer reports
Test Methods
Training Assessments
51
52. Records
Worksheet, notebooks and long books
Manufacturing and packaging instructions
Confidentiality agreements
Change control
Quality system related documents
Quality manual
Validation protocols and reports
Deviation reports
Audit plans
Electronic and hard-copy Quality records
52
53. Test material related documents including
product specification, test material receipt and
reports.
Personal related documents including training
records.
Facility related documents including floor plans,
environmental specifications.
Deviation forms including unplanned deviations
and system failure investigation.
53
54. Distribution Records
It contain name and strength of the product and
description of the dosage form, name and address
of the consignee, date quantity shipped, and lot or
control number of the drug product.
Distribution records include a wide range of
documentation such as invoices, bill of lading
customer receipts, and internal warehouse
storage and inventory records.
54
55. The information required need not be on every
document.
Also customer codes and product codes may be
used as alternates to customers name and
addresses and product names.
Records for distribution shall be maintained in
a manner such that finished batch of a drug can
be traced to the retain level to facilitate prompt
and complete recall of the batch, if and when
necessary.
55
56. Document Required
SOP on distribution of finished
products for sale or sample.
Records of distribution.
56